Loading stock data…
Lifecore Biomedical (LFCR)
$4.96-0.21 (-4.06%)
After Hours$5.10+0.14 (+2.82%)· Last close Jun 29
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lifecore Biomedical, Inc. in the Healthcare sector is trading at $4.96 with a market capitalization of $209M. Wall Street consensus targets $6.83 (3 analysts), implying a +37.8% move over the next 12 months. The stock is currently 45% below its 52-week high of $8.98, remaining 24.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $23.19M↓ | $31.11M↓ | $36.44M↑ | $35.15M↑ | $32.56M |
| Gross Profit | $4.46M↓ | $7.79M↓ | $13.98M↑ | $9.85M↓ | $11.08M |
| Operating Income | -$4.67M↓ | -$3.07M↓ | $2.90M↑ | -$2.18M↓ | -$1.96M |
| Net Income | -$14.98M↓ | -$9.99M↓ | -$1.15M↑ | -$14.77M↓ | -$6.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$208.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
143.78%
Volume
Today's trading volume
421,363
Recent News
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook
Lifecore Biomedical’s analyst narrative has been updated, with a fair value estimate holding at US$6.67, while several Street price targets now cluster closer to the US$5 to US$5.50 range. That shift aligns with recent commentary that balances confidence in the long term opportunity with more cautious views on the timing of commercial ramps and the updated FY26 outlook. As you read on, you will see how these moving parts shape the evolving story and what to watch to stay in sync with it. Wall...
How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations
The clearest shift in the Lifecore Biomedical story sits in price targets, with one bearish analyst moving from US$8.50 down to US$5, even as the model fair value stays at US$6.67. That gap reflects the split you are seeing in recent commentary, where some analysts focus on execution risk and timing around FY26 guidance, while others lean on the longer term opportunity. Read on to see what is driving these views and how you can track the next turns in this evolving narrative. Analyst Price...
Lifecore Biomedical Q1 Earnings Call Highlights
Lifecore Biomedical (NASDAQ:LFCR) executives highlighted new commercial site transfer wins, continued cost reductions, and improving liquidity during the company’s first-quarter 2026 earnings call, while acknowledging a year-over-year revenue decline tied to previously discussed headwinds. Manageme
Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR)
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of all fees and expenses in the first quarter of 2026. The SP500TR and R2000 returned -4.3% and 0.9% respectively, during the […]
When Should You Buy Lifecore Biomedical, Inc. (NASDAQ:LFCR)?
Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it saw significant share price...